SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS

Le résumé fourni par la source

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma-cell disorder characterised by the presence of a monoclonal protein without end-organ damage and is the earliest clinically detectable precursor to multiple myeloma (MM) [ 1 ]. MGUS is common in ageing populations, affecting 5% of adults over 50 years [ 2 , 3 ]. Although all MM is preceded by MGUS, the average annual risk of progression is only ~1% [ 4 , 5 ]. Progression endpoints differ by subtype: non-IgM MGUS typically progresses to MM, IgM MGUS often to lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, and light-chain MGUS to LC-myeloma or AL amyloidosis [ 6 ]. This long preclinical window makes risk communication and monitoring central to care.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.